Abstract: The photosensitized generation of singlet oxygen within tumor tissues during photodynamic therapy( PDT) is self-limiting,a st he already lowo xygen concentrations within tumors is further diminished during the process.I nc ertain applications,t om inimize photoinduced hypoxia the light is introduced intermittently (fractional PDT) to allowt ime for the replenishment of cellular oxygen. This condition extends the time required for effective therapy. Herein, we demonstrated that ap hotosensitizer with an additional 2-pyridone module for trapping singlet oxygen would be useful in fractional PDT.T hus,i nt he light cycle,t he endoperoxide of 2-pyridone is generated along with singlet oxygen. In the dark cycle,t he endoperoxideu ndergoes thermal cycloreversion to produce singlet oxygen, regenerating the 2-pyridone module. As aresult, the photodynamic process can continue in the dark as well as in the light cycles.Cell-culture studies validated this working principle in vitro.
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Photodynamic therapy has,for some time,been considered ap romising method for the treatment of various cancers. [1] Thet herapeutic procedure involves the photosensitized generation in tumor tissues of singlet oxygen, which is cytotoxic and has as hort lifetime,i ncreasing the chances of selective action. There are other aspects of photodynamic therapy (PDT) which makes it appear truly promising,such as an enhanced immune response following aP DT session. [2] Nevertheless,c linical application of PDT seems to limited mostly to superficial lesions. [3] One reason for the limited application of the method is the fact that PDT requires oxygen, but most tumors develop regions of severe hypoxia where photosensitized singlet oxygen generation would not be expected. [4] More problematic is the fact that PDT itself,by rapidly using intracellular oxygen reserves,c reates acute hypoxia. [5] Many studies suggest that fractional (intermittent) delivery of light might be ab etter approach to PDT. [6] Thus, between irradiation periods,t ime is allocated for the replenishment of intracellular oxygen.
Considering the fact that singlet oxygen is the ultimate cytotoxic agent required for effective PDT,w et hought of using chemically generated singlet oxygen for the dark period of fractional PDT,w here photosensitized generation is not possible.I nf act, it would be highly interesting to combine ap hotosensitizer and ac hemical source of singlet oxygen in asingle molecule.
Thee ndoperoxides of 2-pyridone and derivatives have been recognized as reliable chemical sources of singlet oxygen as they undergo clean (no side reactions) cycloreversion reactions to release singlet oxygen with very high yields. [7] [8] [9] In fact, it has been already reported that singlet oxygen produced by the thermal decomposition of 2-pyridone endoperoxides lead to cell death by ap rocess resembling apoptosis in cancer cell cultures. [10] In addition, phthalocyanine [11] and porphyrin endoperoxide [12] derivatives were reported where the endoperoxides are obtained by selfphotosensitization. Thus,i ti se vident that ar ationally designed bifunctional photosensitizer/2-pyridone conjugate may be an optimal agent for an ovel approach to fractional photodynamic therapy.2 ,6-Dibromo (and iodo) distyryl BODIPY derivatives (BODIPY = boron-dipyrromethene) were shown [13] [14] [15] [16] to be promising long-wavelength sensitizers of molecular oxygen. In addition, the versatility of the chemistry of BODIPY derivatives has led to the employment of these molecules more and more frequently in the development of novel strategies towards the improvement of PDT. [17] Based on these considerations,wedesigned abifunctional compound to meet the requirements for enhanced fractional photodynamic therapy.T he operation principle for the generation of singlet oxygen is shown in Figure 1 . When excited at l = 650 nm, the upper dye molecule in the figure (Pyr 6)isexpected to generate singlet oxygen, and some of it will be "stored" in the form of a2 -pyridone endoperoxide (EPO 7). When the irradiation is turned off,asit would be in fractional PDT (for the replenishment of intracellular oxygen), the 2-pyridone-endoperoxide (EPO 7)w ill undergo thermal cycloreversion producing singlet oxygen in the absence of light.
Thes yntheses of the target compounds are shown in Scheme 1. Thekey step is the functionalization of 2-pyridone with an arylaldehyde group.T he aldehyde functionality provides easy access to BODIPY structures,a nd in this case we were able to obtain compound 4 in good yields. Bromination with N-bromosuccinimide (NBS) affords compound 5.I n5,t he presence of the heavy bromine atoms facilitated intersystem crossing, which is essential for photosensitized singlet oxygen generation. Next, to shift the absorption maximum of the BODIPY chromophore to ar egion more relevant for PDT,c ompound 5 was reacted with p-methoxybenzaldeyde to form compound 6.T he distyryl-BODIPY compound 7 was formed after irradiation of 6 in the presence of methylene blue.C ompound 7 has an absorption maximum at l = 667 nm at the red region of the visible spectrum, with an extinction coefficient of 74 200 cm À1 m À1 . We first set out to demonstrate the reversibility of the transformation between the pyridone (PYR 6)a nd the endoperoxide (EPO 7). Fortunately,t he 1 HNMR spectra of the two compounds have well-resolved characteristic signals for both the PYR and EPO forms.P artial 1 HNMR data are shown in Figure 2 . Thet riplet at d = 6.25 ppm is attributable to aproton on the pyridone ring and the AB system between 4.6 and 4.9 ppm, an indicator of endoperoxide formation, is attributable to N-CH 2 protons.S pectrum Ai st he partial 1 HNMR spectra(CDCl 3 ;3 78 8C) demonstrating the reversibility of the interconversion between compound 6 (PYR) and compound 7 (EPO). Spectrum As hows the partial NMR spectrum of the sample (PYR 6)recorded at 0min. Spectrum Bi sthat of the sample after irradiation at l = 650 nm for 15 min in the NMR tube, forming EPO 7 (a very weak stream of oxygen was bubbled through the sample throughout the experiment). The other spectra were recorded at 15 min intervals in the dark at 37 8 8C. Bottom:Relative percentages of 6 and 7 present during the conversionb etween the two forms. The conversion process was monitored by measuring the integrated peak areas for the characteristic NMR signals of each form. Relative percentages of both forms (corresponding to the upper NMR spectra) are given in the table under the plot. The 1 HNMR spectrum of EPO 7 in the same region is presented in Figure 2 ( top) as the other reference spectrum (spectrum B). This spectrum is obtained by irradiation of compound 6.W hen the irradiation was stopped and the solution kept in the dark at 37 8 8C, the spectra gradually evolved from spectrum Bt oF .A tt hat point, the NMR tube was irradiated again for as hort time,w hich clearly regenerated unmistakable resonance signals for the endoperoxide (such as the AB system around d = 4.75 ppm). Thus,itisclear that interconversion between the two forms occurred as long as there was dissolved oxygen present during the irradiation.
Theformation of singlet oxygen was further studied using the selective singlet-oxygen trap molecule 1,3-diphenylisobenzofuran (DPBF). Under irradiation with an LED array at l = 650 nm, halogenated distyryl-Bodipy sensitizes groundstate molecular oxygen to generate singlet oxygen. Thet rap molecule reacts with the singlet oxygen, resulting in adecrease in the absorbance of DPBF at l = 416 nm. As mentioned earlier, during this light cycle the molecule is transformed from the PYR form into the EPO form. When the irradiation at l = 650 nm is switched off,t he EPO form gradually cycloreverts to the PYR form, generating simultaneously singlet oxygen in the dark cycle.The results of this experiment and that of the control, which is the trap compound DPBF (in DMSO) subjected to the dark and light cycles,a re shown in Figure 3 .
Thep erformance of the bifunctional photosensitizer was also studied in HeLa (human cervical cancer cell line) cell cultures.O ur expectation was that EPO 7 would be am ore effective cytotoxic agent compared to as imple photosensitizer in when employed in the dark-light cycle regime (as is done in fractional PDT). Since the apoptotic response is timedependent, amore fair comparison would be to compare the effects of PYR and EPO.S ince both compounds had very limited water solubility,t he non-ionic surfactant cremophor EL was used to deliver the agents within am icellar structure.M icelles were prepared following literature procedures.
[17c] Thesize distribution of the micelles was studied by using dynamic light scattering,which showed that the average size of the micelles carrying embedded 7 or 8 is about 50 nm. HeLa cells were incubated with complete Dulbeccos modified Eagles medium (DMEM) under environmental conditions of 37 8 8C, 5% CO 2 ,a nd 60 %h umidity.C ells were exposed to varying concentrations of the compounds in cremophor EL micelles (9 nm-2.5 mm)a nd illuminated with ar ed light source (l = 655 nm LED array,3 24 mmol m À2 s À1 photon flux) for 10 min in every one hour, which was repeated 24 times.T hus,t he total illumination time was exactly 4h. This 24 hp eriod of light-dark cycles was then followed by a24hincubation period in the dark (total 48 h). Thecontrol group of cells were incubated in the dark for 48 hu nder identical environmental conditions.M TT assays were performed to assess cell viability and cytotoxicity ( Figure 4 ). It was found that even low doses of compound 7 (EPO) results in as ignificant decrease of the cell viability.T he CC 50 values (50 %cytotoxic concentration) of the compounds both in the dark and after irradiation were estimated by fitting am odel with nonlinear regression. TheC C 50 value of compound 7 (EPO) was found to be significantly less than that of 6 (PYR) after intermittent illumination of both (approximately 8.6 nm versus 49.0 nm). This result validates our design as it suggests that initial EPO cycloreversion results in alarge difference in singlet oxygen generation when followed by the application of al ight-dark cycle.A dditionally,w hen considering the reported CC 50 values,E PO 7 is,a se xpected, much more active as ap hotosensitizing cytotoxic agent compared to previously reported Bodipy-based long-wavelength photosensitizers which do not have reversible singlet-oxygen storage modules.
[1f]
In this proof-of-principle study,wehave prepared abifunctional photosensitizer to improve fractional PDT.W ed emonstrated that continuous release of singlet oxygen from the Figure 3 . Decrease in the absorbance(at l = 416 nm) of the trap compound DPBF in the presence (blue line) and the absence (green line;i.e. trap compound DPBF alone) of the EPO/PYR agent (6/7). The reaction was carried out at 37 8 8Ci nDMSO. White bars correspond to the periods of irradiation (L, light cycles) which was carried out using ared LED array irradiatingatl = 650 nm for 30 s. Black bars (D, dark cycles) correspond to the dark periods, where both solutions were kept in the dark for 30 min. Ag entle stream of oxygen was bubbled through the reaction and control samples. There is aslight decrease in the absorbanceofthe control in the light cycle as expected, but no significant change takes place in the dark. Figure 4 . Cell viabilities as determined by MTT assays. Data labeled as "light" refers to results obtained when indicated concentrations of micelle-delivered agents PYR (6)a nd EPO (7)w ere exposed to cycles of light (l = 655 nm, 10 min) and dark (50 min) with atotal of 4hof light exposure, followed by 24 hofincubation in the dark. The label "dark" indicates compounds which had been incubated in the dark only for 48 h.
photosensitizer can be achieved in both light and dark cycles, leading to significant differences in cytotoxic activity in cell culture studies compared to conventional PDT agents.W e propose that when the system is applied in vivo,w hile the oxygen levels in the tumor tissues are replenished for the next round of photosensitized singlet oxygen generation, thermal cycloreversion will continue to produce singlet oxygen in dark, without consuming molecular oxygen. Considering the fact that tumor hypoxia and PDT-induced hypoxia are major problems hindering the broader applicability of PDT,weare confident that bifunctional PDT agents will have apromising future.
